Anish Thomas

Anish Thomas

Auto-generated profile, based on publicly available information

Anish Thomas

Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2019 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ATAnish Thomas
Anish Thomas
YPYves Pommier
Yves Pommier
Irinotecan and topotecan have been widely used as anticancer drugs for the past 20 years. Because of their selectivity as topoisomerase I (TOP1) inhibitors that trap TOP1 cleavage complexes, camptothecins are also widely used to elucidate the DNA repair pathways associated with DNA–protein cross-links and replication stress. This review summarizes the basic molecular mechanisms of action of TOP1 inhibitors, their current use, and limitations as anticancer agents. We introduce new therapeutic strategies based on novel TOP1 inhibitor chemical scaffolds including the indenoisoquinolines LMP400 (indotecan), LMP776 (indimitecan), and LMP744, and on tumor-targeted delivery TOP1 inhibitors using liposome, PEGylation, and antibody–drug conjugates. We also address how tumor-specific determinants such as homologous recombination defects (HRD and BRCAness) and Schlafen 11 (SLFN11) expression can be used to guide clinical application of TOP1 inhibitors in combination with DNA damage response inhibitors including PARP, ATR, CHEK1, and ATM inhibitors.

12 May 2015 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
ATAnish Thomas
Anish Thomas
Stephen LiuStephen Liu
Stephen Liu
DSDeepa S. Subramaniam
Deepa S. Subramaniam
GGGiuseppe Giaccone
Giuseppe Giaccone

1 February 2015 in The Lancet Oncology
Verified
Journal Article
Closed access
ATAnish Thomas
Anish Thomas
ARArun Rajan
Arun Rajan
ABArlene Berman
Arlene Berman
YTYusuke Tomita
Yusuke Tomita
CBChristina Brzezniak
Christina Brzezniak
GGGiuseppe Giaccone
Giuseppe Giaccone

20 March 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
ALAriel Lopez-Chavez
Ariel Lopez-Chavez
ATAnish Thomas
Anish Thomas
ARArun Rajan
Arun Rajan
MRMark Raffeld
Mark Raffeld
BMBetsy Morrow
Betsy Morrow
GGGiuseppe Giaccone
Giuseppe Giaccone
Purpose: We conducted a basket clinical trial to assess the feasibility of such a design strategy and to independently evaluate the effects of multiple targeted agents against specific molecular aberrations in multiple histologic subtypes concurrently. Patients and Methods: We enrolled patients with advanced non–small-cell lung cancer (NSCLC), small-cell lung cancer, and thymic malignancies who underwent genomic characterization of oncogenic drivers. Patients were enrolled onto a not-otherwise-specified arm and treated with standard-of-care therapies or one of the following five biomarker-matched treatment groups: erlotinib for EGFR mutations; selumetinib for KRAS, NRAS, HRAS, or BRAF mutations; MK2206 for PIK3CA, AKT, or PTEN mutations; lapatinib for ERBB2 mutations or amplifications; and sunitinib for KIT or PDGFRA mutations or amplification. Results: Six hundred forty-seven patients were enrolled, and 88% had their tumors tested for at least one gene. EGFR mutation frequency was 22.1% in NSCLC, and erlotinib achieved a response rate of 60% (95% CI, 32.3% to 83.7%). KRAS mutation frequency was 24.9% in NSCLC, and selumetinib failed to achieve its primary end point, with a response rate of 11% (95% CI, 0% to 48%). Completion of accrual to all other arms was not feasible. In NSCLC, patients with EGFR mutations had the longest median survival (3.51 years; 95% CI, 2.89 to 5.5 years), followed by those with ALK rearrangements (2.94 years; 95% CI, 1.66 to 4.61 years), those with KRAS mutations (2.3 years; 95% CI, 2.3 to 2.17 years), those with other genetic abnormalities (2.17 years; 95% CI, 1.3 to 2.74 years), and those without an actionable mutation (1.85 years; 95% CI, 1.61 to 2.13 years). Conclusion: This basket trial design was not feasible for many of the arms with rare mutations, but it allowed the study of the genetics of less common malignancies.

23 October 2013 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
RHRaffit Hassan
Raffit Hassan
AMAndrew C. Miller
Andrew C. Miller
ESElad Sharon
Elad Sharon
ATAnish Thomas
Anish Thomas
JRJames C. Reynolds
James C. Reynolds
IPIra Pastan
Ira Pastan
In patients with advanced chemotherapy-refractory mesothelioma, treatment with the anti-mesothelin immunotoxin SS1P and immunosuppression with pentostatin and cyclophosphamide resulted in marked and durable tumor regressions.

21 November 2022 in Nature Cancer
Verified
Journal Article
Open access
PDF file
YNYoko Nishiga
Yoko Nishiga
ADAlexandros P. Drainas
Alexandros P. Drainas
MBMaya Baron
Maya Baron
DBDebadrita Bhattacharya
Debadrita Bhattacharya
ABAmira A. Barkal
Amira A. Barkal
JSJulien Sage
Julien Sage
Radiation therapy is a mainstay of cancer treatment but does not always lead to complete tumor regression. Here we combine radiotherapy with blockade of the ‘don’t-eat-me’ cell-surface molecule CD47 in small cell lung cancer (SCLC), a highly metastatic form of lung cancer. CD47 blockade potently enhances the local antitumor effects of radiotherapy in preclinical models of SCLC. Notably, CD47 blockade also stimulates off-target ‘abscopal’ effects inhibiting non-irradiated SCLC tumors in mice receiving radiation. These abscopal effects are independent of T cells but require macrophages that migrate into non-irradiated tumor sites in response to inflammatory signals produced by radiation and are locally activated by CD47 blockade to phagocytose cancer cells. Similar abscopal antitumor effects were observed in other cancer models treated with radiation and CD47 blockade. The systemic activation of antitumor macrophages following radiotherapy and CD47 blockade may be particularly important in patients with cancer who suffer from metastatic disease.